Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from May 2023.
Pharmaceuticals
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy -
Read more: Merck Price Negotiation Lawsuit May Face Same Obstacles as 340B Takings Claims Merck Price Negotiation Lawsuit May Face Same Obstacles as 340B Takings Claims
Past 340B litigation highlights that takings challenges to the Medicare price negotiation program face an uphill battle.
-
Read more: FDA Solicits Feedback on the Use of AI and Machine Learning in Drug Development FDA Solicits Feedback on the Use of AI and Machine Learning in Drug Development
The FDA has recently turned its attention to the growing use of artificial intelligence and machine learning in drug development.
-
Read more: Psychiatric Care in Crisis Psychiatric Care in Crisis
The Emergency Department acts as a safety-net for a failing health system, one that places little value on mental health services.
-
Read more: Telemedicine Data Privacy and the Mifepristone Debates Telemedicine Data Privacy and the Mifepristone Debates
Mifepristone’s shifting legal terrain may soon raise new privacy considerations regarding telemedicine data collection, security, and disclosure.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from April 2023.
-
Read more: The European Commission’s New Compulsory Licensing Proposal: A Step Forward? The European Commission’s New Compulsory Licensing Proposal: A Step Forward?
The EU’s effort to establish a Union compulsory license is a step toward harmonizing patent law and creating a more effective single market.
-
Read more: Public Health Product Hops Public Health Product Hops
Are there circumstances for which allowing a product hop resulted in a net benefit to society that exceeded the excess costs associated with the new product?
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from March 2023.
-
Read more: The Federal Judiciary Is Broken — But Not for the Reason You Think The Federal Judiciary Is Broken — But Not for the Reason You Think
While issues of influence affecting Supreme Court Justices attract the most attention, the factors that make Justices targets extend across the entire federal judiciary.
